Skip to main content

Abiraterone News

FDA Approves Akeega for BRCA-Positive Metastatic Prostate Cancer

THURSDAY, Aug. 17, 2023 – The U.S. Food & Drug Administration has approved Akeega (niraparib and abiraterone acetate) for the treatment of BRCA-positive metastatic castration-resistant prostate...

Guideline Updated for Initial Management of Advanced Prostate Cancer

WEDNESDAY, April 12, 2023 – For patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with...

Sun Pharma Announces FDA Approval of Yonsa (abiraterone acetate) to Treat Metastatic Castration-Resistant Prostate Cancer

MUMBAI & PRINCETON, N.J. & KING OF PRUSSIA, Pa. May 23, 2018 --(BUSINESS WIRE)--Sun Pharmaceutical Industries Ltd. and includes its subsidiaries and/or associate companies) and Churchill...

Zytiga (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

HORSHAM, PA, Feburary 8, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga (...

FDA Expands Zytiga’s Use for Late-Stage Prostate Cancer

December 10, 2012 – The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Prostate Cancer

Abiraterone patient information at Drugs.com